목적: 당뇨황반부종에서 유리체내 베바시주맙과 후테논낭하 트리암시놀론 주입술의 병합요법을 각각의 단독요법과 비교하였다. 대상과 방법: 당뇨황반부종이 있는 83명, 90안을 대상으로 각 30안씩 무작위로 유리체내 베바시주맙 주입술 (IVB 군), 후테논낭하 트리 암시놀론 주입술(STTA 군) 및 병합요법(combined 군)을 시행하였고, 술 전 및 술 후 1, 3, 6개월의 시력, 중심황반두께 및 안압의 변화를 비교하였다. 결과: 세 군 모두 중심황반두께의 감소가 술 후 3개월까지 유지되다가 6개월째에 다시 증가하였고, 시력 호전은 술 후 3개월까지 유지되 다가 6개월 후에 다시 감소하는 양상을 보였다. 술 후 초기 1개월간 중심황반두께의 감소량 및 시력 호전량은 병합요법에서 가장 크게 나타 났다(p=0.003, p=0.021). 관찰 기간 중 안내염, 망막박리 등의 심각한 합병증은 관찰되지 않았고, 총 3안에서 안압 상승이 관찰되었다. 결론: 당뇨황반부종에서 유리체강내 베바시주맙과 테논낭하 트리암시놀론 주입술의 병합요법은 각각의 단독요법에 비하여 시력 호전과 중심황반두께 감소에 있어 초기 1개월에 높은 치료 효과를 보였으며, 3개월 이후에는 비슷하였다.

Purpose: To investigate the outcomes of the combined therapy of intravitreal bevacizumab (IVB) and posterior sutbtenon triamconolone acetonide (STTA) injections as compared to single injections of each in patients with diabetic macular edema (DME). Methods: IVB injection (IVB group), STTA injection (STTA group) and combined therapy injection (combined group) were performed randomly for 90 eyes (83 patients) diagnosed with DME. Changes in central macular thickness (CMT), best corrected visual acuity (BCVA) and intraocular pressure (IOP) were compared among groups prospectively at pre-injection and one, three and six months after injection. Results: Reduction of CMT and improvement of BCVA were maintained for three months after treatment in all groups, but CMT and BCVA deteriorated at six months after treatment. The combined therapy group revealed significant reductions in CMT and improvement of BCVA (p=0.003, p=0.021, respectively) for the first month compared to the single treatment group. Elevated IOPs were found in three cases and there was no endophthalmitis or retinal detachment. Conclusions: The combined therapy injection showed significant early improvements in CMT and BCVA for one month. Additionally, the combined therapy revealed similar outcomes as compared with each single treatment after three months.

Purpose: To investigate the outcomes of the combined therapy of intravitreal bevacizumab (IVB) and posterior sutbtenon triamconolone acetonide (STTA) injections as compared to single injections of each in patients with diabetic macular edema (DME). Methods: IVB injection (IVB group), STTA injection (STTA group) and combined therapy injection (combined group) were performed randomly for 90 eyes (83 patients) diagnosed with DME. Changes in central macular thickness (CMT), best corrected visual acuity (BCVA) and intraocular pressure (IOP) were compared among groups prospectively at pre-injection and one, three and six months after injection. Results: Reduction of CMT and improvement of BCVA were maintained for three months after treatment in all groups, but CMT and BCVA deteriorated at six months after treatment. The combined therapy group revealed significant reductions in CMT and improvement of BCVA (p=0.003, p=0.021, respectively) for the first month compared to the single treatment group. Elevated IOPs were found in three cases and there was no endophthalmitis or retinal detachment. Conclusions: The combined therapy injection showed significant early improvements in CMT and BCVA for one month. Additionally, the combined therapy revealed similar outcomes as compared with each single treatment after three months.